Accounting for Innovation: R&D Costs Explained
Embark With Us
JULY 31, 2025
The board is actively evaluating whether certain development-phase costs should be eligible for capitalization, aligning more closely with IFRS and modernizing financial reporting in a knowledge-based economy. A failed clinical trial or adverse regulatory development could trigger impairment or reclassification.
Let's personalize your content